Glucose lowering efficacy of dapagliflozin is reduced in patients w/ eGFR <45 mL/min/1.73 m
2. Not for the treatment of type 1 DM; diabetic ketoacidosis. Predisposing factors to ketoacidosis including low β-cell function reserve resulting from pancreatic disorders (eg, type 1 diabetes, history of pancreatitis or pancreatic surgery), insulin dose reduction, reduced caloric intake or increased insulin requirements due to infections, illness or surgery, & alcohol abuse. Discontinue or consider temporary interruption if ketoacidosis is suspected. Discontinue & prompt treatment should be instituted if necrotizing fasciitis of the perineum (Fournier's gangrene) is suspected. Concomitant use w/ medications known to cause hypoglycemia eg, insulin & insulin secretagogues (eg, sulfonylureas). Interference w/ 1,5-anhydroglucitol assay. Avoid during pregnancy (2nd & 3rd trimester). Lactation. Ped & adolescents.
Sign Out
